1. Home
  2. LNG vs ALNY Comparison

LNG vs ALNY Comparison

Compare LNG & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LNG
  • ALNY
  • Stock Information
  • Founded
  • LNG 1983
  • ALNY 2002
  • Country
  • LNG United States
  • ALNY United States
  • Employees
  • LNG N/A
  • ALNY N/A
  • Industry
  • LNG Oil/Gas Transmission
  • ALNY Biotechnology: Pharmaceutical Preparations
  • Sector
  • LNG Utilities
  • ALNY Health Care
  • Exchange
  • LNG Nasdaq
  • ALNY Nasdaq
  • Market Cap
  • LNG 53.9B
  • ALNY 40.4B
  • IPO Year
  • LNG 1997
  • ALNY 2004
  • Fundamental
  • Price
  • LNG $241.47
  • ALNY $315.75
  • Analyst Decision
  • LNG Strong Buy
  • ALNY Strong Buy
  • Analyst Count
  • LNG 14
  • ALNY 24
  • Target Price
  • LNG $253.64
  • ALNY $345.70
  • AVG Volume (30 Days)
  • LNG 1.6M
  • ALNY 881.7K
  • Earning Date
  • LNG 08-07-2025
  • ALNY 07-31-2025
  • Dividend Yield
  • LNG 0.83%
  • ALNY N/A
  • EPS Growth
  • LNG N/A
  • ALNY N/A
  • EPS
  • LNG 13.71
  • ALNY N/A
  • Revenue
  • LNG $16,739,000,000.00
  • ALNY $2,348,099,000.00
  • Revenue This Year
  • LNG $33.47
  • ALNY $32.73
  • Revenue Next Year
  • LNG $12.47
  • ALNY $31.50
  • P/E Ratio
  • LNG $17.61
  • ALNY N/A
  • Revenue Growth
  • LNG N/A
  • ALNY 17.21
  • 52 Week Low
  • LNG $167.66
  • ALNY $205.87
  • 52 Week High
  • LNG $257.65
  • ALNY $333.70
  • Technical
  • Relative Strength Index (RSI)
  • LNG 55.70
  • ALNY 52.45
  • Support Level
  • LNG $231.60
  • ALNY $312.96
  • Resistance Level
  • LNG $241.48
  • ALNY $324.82
  • Average True Range (ATR)
  • LNG 6.00
  • ALNY 9.14
  • MACD
  • LNG -0.22
  • ALNY -2.23
  • Stochastic Oscillator
  • LNG 72.79
  • ALNY 24.39

About LNG Cheniere Energy Inc.

Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: